Loading clinical trials...

A Study of LY900014 in Elderly and Younger Adult Participants With Type 1 Diabetes Mellitus | Clinical Trials | Clareo Health

COMPLETEDPHASE1

A Study of LY900014 in Elderly and Younger Adult Participants With Type 1 Diabetes Mellitus

Pharmacokinetics and Glucodynamics of LY900014 Compared to Insulin Lispro Following Single Dose Administration in Elderly and Younger Adults With Type 1 Diabetes Mellitus

NCT03166124•Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The purpose of this study is to compare LY900014 with insulin lispro (Humalog) in elderly and younger adults with type 1 diabetes mellitus. Screening is required within 28 days prior to the start of the study. For each participant, the total duration of the clinical trial will be between 3 to 8 weeks.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Are male or female participants with Type 1 Diabetes Mellitus (T1DM)
•Have a body mass index (BMI) of 18.5 to 30.0 kilogram per meter square (kg/m²)
•Have a glycated hemoglobin (HbA1c) less than (\<)9.0 percent (%)
•Have had no episodes of severe hypoglycaemia in the last 6 months

Exclusion Criteria

•Have a history or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (apart from T1DM), hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational product; or of interfering with the interpretation of data
•Have a history of renal impairment
•Have a history of deep vein thrombosis of the leg or repeated episodes of deep leg vein thrombosis in first-degree relatives
•Have proliferative retinopathy or maculopathy and/or severe neuropathy

Locations (2)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.

Mainz, Germany

Neuss, Germany

Key Dates

Start Date

May 24, 2017

Primary Completion Date

November 18, 2017

Completion Date

November 18, 2017

Last Updated

April 30, 2020

Enrollment

ACTUAL participants

Conditions

Diabetes Mellitus, Type 1

Interventions

LY900014

DRUG

Insulin Lispro

DRUG

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

NCT04786262

Diabetes Mellitus, Type 1Impaired Hypoglycemic Awareness+1 more

View study

RECRUITINGNA

Fasted Exercise Training in Type 1 Diabetes (FED-T1D)

NCT06748963

Diabetes Mellitus, Type 1

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 30, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of LY900014 in Elderly and Younger Adult Participants With Type 1 Diabetes Mellitus

Inclusion Criteria

Exclusion Criteria

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

Fasted Exercise Training in Type 1 Diabetes (FED-T1D)

Closed Loop and Education for Hypoglycemia Awareness Restoration

A Research Study of a New Medicine NNC0363-1063 in Participants With Type 1 Diabetes

Achieving Health in Emerging Adults With Diabetes (AHEAD) Program: A Clinical Trial Designed to Understand if Participation in a Clinical Program Developed Specifically to Support Emerging Adults With Type 1 Diabetes Leads to Improved Diabetes Outcomes.

Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes